Facilities & Capacity

Fujifilm to build $188m NC cell culture media plant

The Research Triangle Park facility will significantly expand Fujifilm Irvine Scientific’s cell culture media capacity to feed the projected double-digit growth in demand from industry. The planned 250,000 square-foot facility – construction of which is scheduled to start in spring 2023– will produce animal component-free, dry powder, and liquid media for biomanufacturing customers. The site in Research Triangle Park (RTP), North Carolina will be the latest in Fujifilm Irvine Scientific’s cell culture media network, joining production sites in Santa Ana…

CGT Catapult looks to Edinburgh to create an iPSC cluster

CGT Catapult says its venture into Edinburgh, Scotland and northern England will focus on the development and production of induced pluripotent stem cells (iPSCs). The Cell and Gene Therapy Catapult (CGT Catapult) announced in June 2021 that it would construct offices and laboratories in Edinburgh, Scotland to support the cell and gene therapy sector and drive product development but did not disclose a specific modality. Now, the organization has confirmed to BioProcess Insider that its move to create a cluster…

Twist’s ‘Factory of the Future’ to ship gene products from January

Twist Bioscience will begin shipping synthetic genes from its Portland, Oregon production plant in January, after investing around $87 million over the past two years. For the full fiscal year 2022, DNA synthesis firm Twist Bioscience reported total revenues of $203.6 million and orders of $226 million, respectively up 54% and 42% year-on-year. This included around $80 million in gene production for Twist’s partner SynBio, a collaboration inked in 2017 that sees Twist manufacture synthetic DNA up to 3.2 kilobases in length…

KBI expansion strategy in question following CEO’s swift exit

Just six months after accepting the role, Mark Womack is no longer serving as the CEO of KBI Biopharma and Selexis. The firm released a statement detailing that Tim Lowery, president of JSR Life Sciences, has been appointed as interim CEO as the company searches to identify someone for a permanent position. The reasons behind his departure have not been disclosed despite BioProcess Insider reaching out to Womack directly for additional information. However, a spokesperson for KBI told us that…

MilliporeSigma invests $300m to expand biosafety capacity in Maryland

MilliporeSigma says global demand has driven its decision to increase biosafety testing capacity at its Rockville, Maryland facility. MilliporeSigma – the life sciences division of Germany’s Merck KGaA – has invested more than €290 million ($300 million) at its Rockville site, which it claims is the largest biosafety testing investment in the company’s history. The contract development manufacturing organization (CDMO) says the decision to expand is in response to the global demand for these services increasing at a double-digit rate. “Biosafety testing…

Bridgewest picks up another Pfizer plant down under

Private investment firm Bridgewest Group has signed a definitive agreement to buy Pfizer’s sterile injectable manufacturing facility  in Western Australia. Pfizer’s manufacturing facility is located in Bentley, a Perth suburb in Western Australia. The plant is authorized to supply drug products in over 90 countries across the globe and approvals have been granted by various regulatory bodies, including the Food and Drug Administration (FDA), Therapeutic Goods Administration (TGA), and the European Union (EU). According to Bridgewest, the facility has blow…

Second Irish site aims to enhance biopharma’s security of supply, says Avantor

Avantor has opened a 69,000 square-foot storage and distribution site in Dublin, Ireland to serve biomanufacturers in the region. The facility, financials of which have not been divulged, will offer Avantor’s customers cGMP warehousing, on-site clean rooms, batch-to-batch traceability, custom palletization, inbound and outbound product quality inspections, and vendor managed inventory solutions. “This new facility will expand capacity in the country and streamline processes for our customers,” Ger Brophy, EVP of Biopharma Production at Avantor told BioProcess Insider. “We also…

Catalent mothballing recently bought UK plant

CDMO Catalent will delay bringing new capital expenditure projects in Oxford and Princeton, New Jersey online as it looks to keep utilization rates stable during the post-COVID period. Correction November 17: The original headline suggested Catalet was mothballing both the Oxford and Princeton site. While this is the case for the Oxford site, it is only the expanson at Princeton that is on hold and it continues to operate. Catalent expanded its manufacturing footprint in April this year after acquiring…

WuXi Vaccines buys Harbour BioMed China facility

The manufacturing facility in Suzhou, China will support vaccine development and production for its global partners, says WuXi Vaccines. Contract development and manufacturing organization (CDMO) WuXi Vaccines says the facility acquired from Harbour BioMed will be its first standalone vaccine development and production plant located in China. “Safe and effective vaccines play an increasingly important role in preventive healthcare,” Jian Dong, CEO of WuXi Vaccines told us. “There is increasing demand for vaccines CDMO services from our global clients as…

Aragen sets it sights on biologics manufacturing with India facility

CDMO Aragen Life Sciences plans to build a biologics manufacturing plant in Bangalore, India, the firm told BioProcess Insider at CPhI Frankfurt. Chief commercial officer Ramesh Subramanian of the contract development manufacturing organization (CDMO) Aragen says the facility, of which financial details have not been disclosed, will manufacture monoclonal antibodies (mAbs) “for now.” According to the firm, the Bangalore facility will initially include 2 x 500 L sub-unit bioreactors but has the capacity to add a further 2 x 2,000…